Weed Growth Fund (OTC:WEDG) Stock, Quote.Headers.trade-ideas

Weed Growth Fund Inc is engaged in the investment, acquisition, operation, and management of, intellectual property and business ventures in hemp, medicinal cannabis, legalized cannabis, and related industries.

News

Penny Stocks

SEDG

WEDG

SolarEdge Technologies (NASDAQ: WEDG) shares are trading lower by roughly 1.16% to $180.52 Monday afternoon. The stock is lower by 24% over the trailing five sessions after the company came out with weak third-quarter guidance.

What Happened With Earnings Last Week?

What&#39;s Going On With SolarEdge Stock?

WEED GROWTH FUND INC by Weed Growth Fund, Inc.

Weed Growth Fund Inc

WEDGEMOUNT RES CORP by Wedgemount Resources Corp.

Wedgemount Resources Corp

<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.cybin.com%2F&amp;esheet=54177898&amp;newsitemid=20250113186119&amp;lan=en-US&amp;anchor=Cybin+Inc.&amp;index=1&amp;md5=0549f47c7f87e6bb3934ed61d7073e10">Cybin Inc.</a> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CYBN#NYSE">CYBN</a>) (Cboe CA:CYBN) ("Cybin" or the "Company"), a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options, is pleased to provide a year-end summary of its key accomplishments in 2024 and upcoming milestones for 2025.
"In 2024, we made significant progress toward our goal of transforming the mental health treatment landscape," said Doug Drysdale, Chief Executive Officer of Cybin. "Our clinical pipeline of tryptamine serotonin receptor agonists – notably CYB003, our proprietary deuterated psilocin program in development for the adjunctive treatment of MDD, and CYB004, our deuterated dimethyltryptamine, in intramuscular ("IM") form being developed for the treatment of GAD - achieved several critical benchmarks."
"It's noteworthy that in March 2024, CYB003 received FDA Breakthrough Therapy Designation. Among its many benefits, this designation provides an expedited review pathway and the potential to accelerate drug development timelines. It also includes all "fast track" program features and acknowledges the significant unmet medical need for more effective treatments of MDD. This is especially gratifying in light of our Phase 2 study results of CYB003 in MDD, which showed remarkable efficacy at 12 months, including a 100% response rate and a 71% remission rate among participants who received two 16 mg doses. With these outstanding findings in hand, we initiated PARADIGM&#x2122;, our multinational pivotal Phase 3 program, evaluating CYB003 in MDD patients. We also commenced our Phase 2 proof-of-concept study of CYB004 in GAD. I'm proud of our Research and Development team and the tremendous progress made in a relatively short amount of time."

CYBN

Cybin Highlights 2024 Progress, Launches Phase 3 Study for CYB003 to Treat Major Depressive Disorder

Apyx Medical Corporation (NASDAQ:<a href="https://www.benzinga.com/stock/APYX#NASDAQ">APYX</a>) (the "Company"), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion&#xAE;, today reported preliminary revenue results for the fourth quarter and full year ended December 31, 2024.
Preliminary Fourth Quarter 2024 Revenue Summary:
<ul>
<li>Total revenue expected to be in a range of approximately $14.1 to $14.3 million, representing a decrease of 4% to 3% year-over-year.
<ul>
<li>Advanced Energy revenue expected to be in a range of approximately $12.0 to $12.2 million, which is relatively flat year-over-year.</li>
<li>OEM revenue expected to be approximately $2.1 million, representing a decrease of 17% year-over-year. &nbsp;</li>
</ul>
</li>
</ul>
Preliminary Full Year 2024 Revenue Summary:
<ul>
<li>Total revenue expected to be in a range of approximately $48.0 to $48.2 million, representing a decrease of 8% year-over-year.
<ul>
<li>Advanced Energy revenue expected to be in a range of approximately $38.5 to $38.7 million, representing a decrease of 11% year-over-year.</li>
<li>OEM revenue expected to be approximately $9.5 million, representing growth of 6% year-over-year.</li>
</ul>
</li>
</ul>

Guidance

APYX

Apyx Medical Announces Q4 2024 Revenue Between $14.1M-$14.3M, A 3%-4% Decrease YOY; Advanced Energy Revenue Flat At $12.0M-$12.2M; OEM Revenue Down 17% To $2.1M; FY24 Revenue Between $48.0M-$48.2M, An 8% Decrease YOY; Advanced Energy Down 11% To $38.5M-$38.7M; OEM Up 6% To $9.5M.

When big names like Intel Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTC#NASDAQ">INTC</a>), Airbnb Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABNB#NASDAQ">ABNB</a>), and Joby Aviation Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JOBY#NYSE">JOBY</a>) land on JPMorgan's <a href="https://www.benzinga.com/trading-ideas/short-ideas">short ideas radar</a>, it's worth a closer look. 
Analysts are flagging unique headwinds for each company—and they're not mincing words about the downside risks.
<h2 class="wp-block-heading">Intel: A Tech Giant In Transition</h2>
JPMorgan analyst Harlan Sur holds an Underweight rating on Intel. He cautions that the chipmaker&#8217;s efforts to right-size operations and advance its product roadmap may not deliver quick wins. Amid tighter semiconductor capital spending and ongoing manufacturing challenges, Intel appears stuck between a rock and a hard pivot. 
Sur's outlook suggests the company may face more hurdles before it reclaims its industry dominance.
Read Also:<a href="http://Intel Stock Has Fallen Over 58% In 1 Year, But Citi Maintains 'Neutral' Rating On Expected Replacement Of Pat Gelsinger In A 'Couple Of Months'"> Intel Stock Has Fallen Over 58% In 1 Year, But Citi Maintains &#8216;Neutral&#8217; Rating On Expected Replacement Of Pat Gelsinger In A &#8216;Couple Of Months&#8217;</a>
<h2 class="wp-block-heading">Airbnb: Heavy Luggage To Carry</h2>
JPMorgan analyst Doug Anmuth remains neutral on Airbnb, though his assessment leans toward stormy skies rather than sunny getaways. Major concerns that Anmuth sees with the investment case for Airbnb are:
<ol>
<li>squeezed margins from new initiatives</li>
<li>increased marketing expenses</li>
<li>slow core growth</li>
</ol>
Add a lofty valuation to the mix, and Airbnb is carrying more baggage than a fully booked red-eye flight. 
The stock's <a href="https://www.benzinga.com/quote/ABNB/short-interest">heavy short interest</a> only fuels the mixed sentiment swirling around the vacation rental giant.
<h2 class="wp-block-heading">Joby Aviation: Sky-High Expectations, Grounded Concerns</h2>
Flying taxis might sound futuristic, but JPMorgan analyst Bill Peterson isn't buying into the hype—yet. Despite potential catalysts like certification progress in 2025, Peterson keeps Joby at Underweight. He warns that speculative tech enthusiasm has already pushed the stock beyond its fundamentals. 
Investors may want to buckle up for turbulence as regulatory and market realities set in.
<h2 class="wp-block-heading">Investor Takeaway</h2>
From chips to rentals to flying cars, JPMorgan analysts suggest a cautious approach to these short ideas. Execution risks are high, and excitement may not be enough to keep these stocks in the air.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/news/25/01/42922091/spacex-apple-airbnb-and-more-companies-pitch-in-to-support-california-residents-after-wildfires-we-want-to-help">SpaceX, Apple, Airbnb And More Companies Pitch In To Support California Residents After Wildfires: &#8216;We Want To Help&#8217;</a></li>
</ul>
Photo: Shutterstock

Analyst Color

Short Ideas

Travel

Analyst Ratings

Tech

Trading Ideas

General

ABNB

INTC

JOBY

Why Intel, Airbnb, Joby Aviation Are Among JPMorgan's Short Ideas

Needham analyst David Saxon reiterates RxSight (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RXST#NASDAQ">RXST</a>) with a Buy and maintains $66 price target.

Price Target

Reiteration

RXST

Needham Reiterates Buy on RxSight, Maintains $66 Price Target

Fastenal Company (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FAST#NASDAQ">FAST</a>) will release its fourth-quarter financial results, before the <a href="https://www.benzinga.com/quote/FAST/earnings">opening bell, on Friday, Jan. 17, 2025.</a>
Analysts expect the Winona, Minnesota-based company to report quarterly earnings at 48 cents per share, up from 46 cents per share in the year-ago period. Fastenal projects quarterly revenue of $1.84 billion, compared to $1.76 billion a year earlier, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
On Dec. 11, Stifel analyst Brian Butler downgraded Fastenal from Buy to Hold and maintained the price target of $86.
With the recent buzz around Fastenal, some investors may be eyeing potential gains from the company's dividends too. Fastenal offers an annual dividend yield of 2.18%, which is a quarterly dividend amount of 39 cents per share ($1.56 a year).
So, how can investors exploit its dividend yield to pocket a regular $500 monthly?
To earn $500 per month or $6,000 annually from dividends alone, you would need an investment of approximately $275,489 or around 3,846 shares. For a more modest $100 per month or $1,200 per year, you would need $55,083 or around 769 shares.
To calculate: Divide the desired annual income ($6,000 or $1,200) by the dividend ($1.56 in this case). So, $6,000 / $1.56 = 3,846 ($500 per month), and $1,200 / $1.56 = 769 shares ($100 per month).
Note that dividend yield can change on a rolling basis, as the dividend payment and the stock price both fluctuate over time.
How that works: The dividend yield is computed by dividing the annual dividend payment by the stock&#8217;s current price.
For example, if a stock pays an annual dividend of $2 and is currently priced at $50, the dividend yield would be 4% ($2/$50). However, if the stock price increases to $60, the dividend yield drops to 3.33% ($2/$60). Conversely, if the stock price falls to $40, the dividend yield rises to 5% ($2/$40).
Similarly, changes in the dividend payment can impact the yield. If a company increases its dividend, the yield will also increase, provided the stock price stays the same. Conversely, if the dividend payment decreases, so will the yield.
Price Action: Shares of Fastenal fell 1.8% to close at $71.63 on Friday.
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="How to Find Dividend Stocks: Scan, Analyze, and Capture with Benzinga Pro" width="500" height="281" src="https://www.youtube.com/embed/pVF0O2lsEH4?start=1&#038;feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>
Read More: 
<ul>
<li><a href="https://www.benzinga.com/25/01/42923396/wall-streets-most-accurate-analysts-weigh-in-on-3-real-estate-stocks-with-over-7-dividend-yields-2">Wall Street&#8217;s Most Accurate Analysts Weigh In On 3 Real Estate Stocks With Over 7% Dividend Yields</a></li>
</ul>
Image: Shutterstock

Earnings

Long Ideas

Markets

FAST

How To Earn $500 A Month From Fastenal Stock Ahead Of Q4 Earnings

Immunovant, Inc. (NASDAQ:<a href="https://www.benzinga.com/stock/IMVT#NASDAQ">IMVT</a>), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today announced that it has agreed to sell an aggregate of 22,500,000 shares of common stock at a purchase price of $20.00 per share to three institutional accredited investors in a private investment in public equity (PIPE). Immunovant anticipates receiving aggregate gross proceeds of approximately $450 million from the PIPE. The PIPE is expected to close on or about January 15, 2025, subject to the satisfaction of customary closing conditions. Immunovant expects to use the proceeds from the PIPE for the advancement of its development pipeline, working capital and other general corporate purposes.

Offerings

IMVT

Immunovant Announces $450M Private Placement Of 22.5M Shares Of Common Stock At A Purchase Price Of $20.00 Per Share To Three Institutional Accredited Investors In A Private Investment In Public Equity

Anterix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATEX#NASDAQ">ATEX</a>) and the <a href="https://www.globenewswire.com/Tracker?data=JXURq9r1YwffTCmTM7pmk9WAfXpNgXE8Sc-vwzrZl_HPlHIJMglRIvazysLOXN5F_QQosXEjFcdC9Fh5EhgE53oHsxRaOUSI8wzRUFG8p1c=">Lower Colorado River Authority</a> announced today that LCRA has contracted with Anterix to purchase additional 900 MHz wireless broadband licenses from Anterix that will extend LCRA's ability to support future growth in Texas. This agreement builds upon LCRA's <a href="https://www.globenewswire.com/Tracker?data=mn8Eo48-TxKH9eZStFuMsPnn0mTVCGsuPlN44OqPUYLrSHk_A56VBJiDNWDu71crqC40UIlBJJ0QwVXlJsE3nP1XAB0tJ7fUOGvr6yKSAaOjw0kF6n-SB7Jmyq2MnSWMxpowzJc-6xRGj5mvvm0hHnGvGLSRyDi-C5anoo6XwlOnMeaIw566I6v2s1wn6X5JWmq6hd5XXerOhgDmCkpeE_0KsFDRpMMDIbiSwjL2haA=">initial purchase</a> of 900 MHz licenses from Anterix announced in April 2023.

ATEX

Anterix Expands Partnership with LCRA, Providing Additional 900 MHz Licenses for Texas Growth

Peer-reviewed data highlights successful clinical study with 35.5% clot burden reduction, validating the safety, efficacy, and efficiency of AlphaVac F1885 System in pulmonary embolism treatment.
AngioDynamics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANGO#NASDAQ">ANGO</a>), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving patient quality of life, today announced the publication of the results from the Acute Pulmonary Embolism Extraction Trial with the AlphaVac System (APEX-AV) in the Journal of the Society for Cardiovascular Angiography &amp; Interventions (JSCAI). The article, "Novel Mechanical Aspiration Thrombectomy in Patients with Acute Pulmonary Embolism: Results from the Prospective APEX-AV Trial," was published December 27, 2024.
Pulmonary embolism (PE), a potentially life-threatening condition, affects approximately 900,000 individuals annually in the United States, with 10-30% of cases resulting in death within one month of diagnosis, according to the American Lung Association.1
The primary efficacy endpoint of the APEX-AV trial was the reduction in RV/LV ratio between baseline and 48 hours post-procedure. The primary safety endpoint was the rate of MAEs, including events such as major bleeding and serious device-related clinical deterioration, pulmonary vascular injury, and cardiac injury within the first 48 hours. Patients were followed for 30 days post-index procedure. The results demonstrated the device as a safe and effective treatment for acute intermediate-risk PE with a significant reduction in RV/LV ratio and clot burden with a low rate of adverse events.
The APEX-AV trial demonstrated a 35.5% reduction in clot burden (via the Modified Miller index score), comparing favorably to other mechanical aspiration devices on the market.2 The unique design features of the device, including its funnel tip, optional wireless navigation, and blood loss mitigation, contributed to clinically significant improvements in both safety and efficacy.

Biotech

ANGO

AngioDynamics Announces 35.5% Clot Reduction With AlphaVac F1885 System in Trial, Meeting Primary Endpoints In Pulmonary Embolism Treatment Published In The Journal Of The Society For Cardiovascular Angiography & Interventions Titled "Novel Mechanical Aspiration Thrombectomy In Patients With Acute Pulmonary Embolism: Results From The Prospective APEX-AV Trial"

Anavex Life Sciences Corp. ("Anavex" or the "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVXL#NASDAQ">AVXL</a>), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders, today announced that over three years of continuous treatment with blarcamesine (ANAVEX&#xAE;2-73) demonstrated significantly reduced clinical decline showing continued clinically and meaningful benefit for early Alzheimer's disease patients.

AVXL

Anavex Reports Long-Term Benefits of Blarcamesine in Slowing Early Alzheimer's Disease Progression

Health Catalyst, Inc. ((", Health Catalyst, ", NASDAQ:<a href="https://www.benzinga.com/stock/HCAT#NASDAQ">HCAT</a>), a leading provider of data and analytics technology and services to healthcare organizations, today announced it has signed a definitive agreement to acquire Upfront Healthcare Services, Inc. ("Upfront"), a next-generation patient engagement platform provider. Health Catalyst anticipates the acquisition will close in the first quarter of 2025. Upfront provides a market-leading patient activation and engagement platform and a proprietary strategic marketing analytics and content personalization solution for healthcare enterprises. Upfront's automated patient acquisition and retention solutions enable healthcare organizations to win loyalty and guide every patient to optimal care by leveraging hyper-personalized experiences. The combination of Upfront's patient acquisition and scheduling expertise with Health Catalyst's current robust patient engagement portfolio is expected to strengthen the patient experience foundation set by Twistle Patient Engagement by Health Catalyst&#x2122; and the Lumeon by Health Catalyst&#x2122; Care Orchestration platform, which both help patients stay informed throughout the care process. Health Catalyst also looks forward to integrating Upfront's technology into its offerings, as Upfront's technology analyzes clinical, sociodemographic, and patient-reported data to digitally guide patients to the care they need, helping care providers reengage patients, promote appointment attendance, streamline scheduling and referrals, and improve care transitions. Bolstered by the data foundation and deep analytical insights provided by Health Catalyst Ignite&#x2122; Data and Analytics, the combination of Upfront's technology and Health Catalyst Ignite&#x2122; will aim to help healthcare clients provide their patients with the best possible care. &nbsp;

HCAT

Health Catalyst Announces Acquisition Of Upfront Healthcare Services, Expanding Patient Engagement Capabilities; Terms Not Disclosed

levation Oncology, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ELEV#NASDAQ">ELEV</a>), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs, today announced program updates and upcoming milestones.
"We are rapidly advancing EO-3021 to address significant unmet needs in treating earlier lines of advanced gastric/GEJ cancer, where we believe we have a unique ability to improve on the standard of care," said Joseph Ferra, President and Chief Executive Officer of Elevation Oncology. "As we enter 2025, we are honing our focus, leveraging the competitive anti-tumor activity and differentiated safety profile of EO-3021 to explore combination approaches in the first- and second-line settings. With our Phase 1 clinical trial ongoing and now enrolling both monotherapy and combination cohorts, we are in a leading position to explore the compelling potential of EO-3021, our differentiated Claudin 18.2 ADC, to improve outcomes for people living with advanced gastric/GEJ cancer."

ELEV

Elevation Oncology Advances EO-3021 Trials to Target Advanced Gastric and GEJ Cancers with Improved Care

MultiPlan consolidates cloud infrastructure to establish a scalable foundation for growth, bring new products to market faster and better support its clients and the patients and members they serve with solutions that improve affordability, quality, and transparency.
MultiPlan Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MPLN#NYSE">MPLN</a>), a leading provider of technology and data solutions that improve affordability, quality and transparency in healthcare, will consolidate its cloud infrastructure on Oracle Cloud Infrastructure (OCI) to support its previously disclosed digital transformation. OCI will also help MultiPlan better support its clients' needs by improving efficiency and creating a more flexible infrastructure that meets evolving market demands.

MPLN

ORCL

MultiPlan Consolidates Cloud Infrastructure On Oracle To Enhance Growth And Accelerate Product Launches, And Support Clients And Patients Efficiently

<ul>
<li>Anticipates multiple clinical updates in the next 12-18 months, including further progress from two ongoing clinical programs and initiation of therapeutic dosing of one new asset based on its next generation targeted radiopharmaceutical technology platform</li>
<li>Four additional new assets being evaluated for IND development, to be guided by first-in-human images</li>
<li>Making progress on plans to expand manufacturing capabilities by improving efficiencies of existing facilities and building out recently acquired sites, while evaluating additional capacity expansion opportunities</li>
<li>Preliminary unaudited cash, cash equivalents and short-term investments of $227.8M as of December 31, 2024 expected to be sufficient to fund current planned clinical milestones and operational investments into late 2026</li>
<li>Company to present updates at 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2025, at 3:45 p.m. PT &nbsp;</li>
</ul>
SEATTLE, Jan. 13, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective," the "Company," "we," "us," and "our") (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CATX#NYSE">CATX</a>), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced strategic priorities for the next 12-18 months.

CATX

Perspective Therapeutics Announced Clinical Updates Expected In 12-18 Months, Has $227.8M In Funds, Expansion Of Manufacturing Capabilities

JP Morgan analyst Matthew Boss maintains Boot Barn Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BOOT#NYSE">BOOT</a>) with a Overweight and raises the price target from $188 to $200.

BOOT

JP Morgan Maintains Overweight on Boot Barn Holdings, Raises Price Target to $200

– Completed enrollment in Phase 3 ENTRUST trial in patients with severe hypertriglyceridemia (SHTG); topline 26-week data expected in the second half of 2025 –
– The Phase 3 ENLIGHTEN program in patients with non-cirrhotic (F2-F3) and compensated cirrhotic (F4) metabolic dysfunction-associated steatohepatitis (MASH) continues to enroll patients across both trials –
– Cash, cash equivalents, and marketable securities totaled approximately $440 million as of December 31, 2024 –
SAN FRANCISCO, Jan. 13, 2025 (GLOBE NEWSWIRE) -- 89bio, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ETNB#NASDAQ">ETNB</a>), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today provided a corporate update and business outlook for 2025.

ETNB

89bio Announces Completion Of Enrollment In Phase 3 ENTRUST Trial For Severe Hypertriglyceridemia; Topline Data Expected In H2 2025. Phase 3 ENLIGHTEN Program For MASH Continues Enrollment. Cash And Equivalents Total $440M As Of Dec 31, 2024

Jupiter Neurosciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JUNS#NASDAQ">JUNS</a>) ("Jupiter" or the "Company"), a clinical-stage pharmaceutical company developing JOTROL&#x2122;, a patented resveratrol-based platform, today announced a strategic focus on targeting the NLRP3 inflammasome in all upcoming clinical trials. This shift aims to unlock new therapeutic potential for neurodegenerative diseases, longevity, and aging, positioning the Company at the forefront of innovation in neuroinflammation treatments.
The NLRP3 inflammasome is a key inflammation driver linked to central nervous system (CNS) disorders, metabolic diseases, and aging-related conditions. JOTROL, Jupiter's flagship product, overcomes resveratrol's historical challenges of poor bioavailability and gastrointestinal side effects. With its ability to safely reach therapeutic levels in plasma and cross the blood-brain barrier, JOTROL represents a groundbreaking advance for targeting neuroinflammatory pathways like NLRP3.

JUNS

Jupiter Neurosciences Announces Strategic Focus On NLRP3 Inflammasome Targeting In Clinical Trials For Neurodegenerative Diseases With JOTROL Platform

Expects full year net revenue between $486 and $488 million and adjusted EBITDA between $(23) and $(21) million
 &nbsp;

PRPL

Purple Innovation Expects FY24 Revenue Of $486M-$488M (Prior $490M-$510M) Vs $489.56M Est

Kratos Defense &amp; Security Solutions, Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KTOS#NASDAQ">KTOS</a>), a technology company in Defense, National Security and Global Markets, announced today that it has recently received an approximate $100 million total potential value hypersonic system program award.&nbsp;Approximately $15 million of funding has been received by Kratos at contract award, with significant increased funding expected in the second half of Kratos fiscal year 2025. Under the new program contract award, Kratos will provide engineering, systems and hardware. Work related to the program will be performed at secure Kratos fabrication, manufacturing and system integration facilities.&nbsp;Due to competitive,&nbsp;security related and other considerations, no additional information will be provided.

Contracts

KTOS

Kratos Receives New Hypersonic System Program Award With Total Potential Value Of ~$100M

Reported positive six-month data from ADVANCED-2 trial of TARA-002 in patients with NMIBC
Completed approximately $100 million public offering, extending runway into 2027
Initial data from 12-month evaluable NMIBC patients in ADVANCED-2 trial expected in mid-2025; Results from a futility analysis of approximately 25 six-month evaluable BCG-Unresponsive patients expected by the end of 2025
Dosing of first patient in THRIVE-3 registrational trial of IV Choline Chloride in patients dependent on parenteral support expected in 1H 2025
Results from additional cohorts of Phase 2 STARBORN-1 trial of TARA-002 in pediatric LMs patients expected by the end of 1H 2025
NEW YORK, Jan. 13, 2025 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TARA#NASDAQ">TARA</a>), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today highlighted recent updates and anticipated 2025 milestones.

TARA

Protara Therapeutics Announces 6-Month Data From ADVANCED-2 Trial; Expects New Data Mid-2025, Begins Dosing In THRIVE-3 Trial In H1 2025, Awaits Results For STARBORN-1 Trial By End Of H1 2025.

On Monday, Artelo Biosciences Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARTL#NASDAQ">ARTL</a>) completed a safety review of the first cohort of eight healthy volunteers in the company's Phase 1 study of ART26.12.&nbsp;
ART26.12 is the lead compound in Artelo's proprietary Fatty Acid Binding Protein (FABP) platform and is believed to be the first-ever selective FABP5 inhibitor to enter clinical trials.
FABPs are a family of intracellular proteins that chaperone lipids essential to normal cellular function. FABP is overexpressed and associated with abnormal lipid signaling in several pathologies.&nbsp;
In development as a non-opioid approach to the management of painful neuropathies, ART26.12 has already demonstrated significant promise in multiple preclinical pain models, including chemotherapy-induced peripheral neuropathy, diabetic neuropathy, cancer bone pain, and osteoarthritis.
Based on the safety profile of ART26.12 in preclinical studies, the company looks forward to learning from the initial safety, pharmacokinetic, and biomarker data from this ongoing human study, which is expected to be completed during the first half of 2025.
With dosing already underway, the next cohort in the Phase 1 study will provide additional insight into the development.
Results from the current Phase 1 single ascending dose study are intended to determine the most suitable doses of ART26.12 to utilize in a multiple ascending dose study evaluating ART26.12 in healthy volunteers planned for the second half of 2025.
In December, Artelo Biosciences announced the presentation of preliminary data on ART27.13, a benzimidazole derivative being studied for <a target="_blank" href="https://www.benzinga.com/pressreleases/24/12/g42390296/artelo-biosciences-announces-presentation-of-phase-1-data-with-art27-13-in-cancer-related-anorexia" rel="noreferrer noopener">cancer-related anorexia</a>.
Artelo is evaluating ART27.13 in the Phase 1/2 trial in cancer-related anorexia, which is currently enrolling Phase 2 of the study.
In Phase 1, ART27.13 was orally administered at 150 to 650 microgram doses.
The investigational drug was well tolerated, with only mild to moderate adverse events observed in a minority of participants.
At one month of treatment, two-thirds of participants showed evidence that the drug was impacting their weight loss, with either stabilization or reversal of weight loss associated with their cancer.
Phase&nbsp;2 is accruing participants at a 650 microgram dosage with planned escalation at 4-week intervals up to a dose of 1300 micrograms per day. The study is expected to complete enrollment during the first half of 2025.
Price Action: ARTL stock closed at $1.16 on Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/01/42925721/biontech-positioned-for-long-term-growth-amid-oncology-transition" target="_blank" rel="noreferrer noopener">BioNTech Positioned For Solid Growth Amid Oncology Transition: Analyst</a></li>
</ul>

Comments

Weed Growth Fund

Weed Growth Fund (WEDG) Forecast

Weed Growth Fund (OTC:WEDG) Stock, Quote.Headers.trade-ideas

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga